New meningitis vaccine enters first human tests

NCT ID NCT07374510

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new vaccine designed to protect against several types of meningococcal bacteria, which can cause meningitis and bloodstream infections. Researchers will enroll 150 healthy people aged 2 to 59 to check the vaccine's safety and how well it triggers an immune response. Participants will receive different doses of the experimental vaccine, an existing vaccine, or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Group ACYW135X Meningococcal Conjugate Vaccine

What this could lead to

If successful, this could lead to a new vaccine that protects against several types of meningococcal bacteria, which cause serious infections like meningitis.

What could go wrong

This is an early Phase 1 trial with only 150 participants, so it is primarily checking safety and immune response. The vaccine may not work as hoped or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGOCOCCAL MENINGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningococcal meningitis meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.